View More Recent Stories

Jul 12, 2021 07:00AM Lyra Therapeutics to Present at Upcoming Virtual Healthcare Conference
Jul 12, 2021 07:00AM Lyra Therapeutics to Present at Upcoming Virtual Healthcare Conference
Jun 30, 2021 07:04AM Lyra Therapeutics (LYRA) Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients with Chronic Rhinosinusitis
Jun 30, 2021 07:00AM Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients with Chronic Rhinosinusitis
Jun 30, 2021 07:00AM Lyra Therapeutics Announces Positive Topline Results of Pharmacokinetic Study of LYR-210 in Patients with Chronic Rhinosinusitis
Jun 8, 2021 04:30PM Lyra Therapeutics (LYRA) Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for LYR-210 for the Treatment of Chronic Rhinosinusitis
Jun 8, 2021 04:30PM Lyra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for LYR-210 for the Treatment of Chronic Rhinosinusitis
Jun 2, 2021 07:15AM Lyra Therapeutics (LYRA), LianBio Announce Strategic Partnership and Exclusive License Agreement to Develop and Commercialize LYR-210 in Greater China and Other Asian Markets
Jun 2, 2021 07:00AM Lyra Therapeutics and LianBio Announce Strategic Partnership and Exclusive License Agreement to Develop and Commercialize LYR-210 in Greater China and Other Asian Markets
Jun 1, 2021 07:00AM Lyra Therapeutics to Present at the William Blair 41st Annual Growth Stock Conference
May 24, 2021 07:00AM Lyra Therapeutics To Present At The Jefferies Virtual Healthcare Conference
May 11, 2021 04:05PM Lyra Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 6, 2021 04:05PM Lyra Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
Apr 27, 2021 08:00AM Lyra Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update
Apr 12, 2021 06:15AM Lyra Therapeutics (LYRA) Reports Positive Full Data Set from LANTERN Phase 2 Study of LYR-210
Apr 11, 2021 03:36PM Lyra Therapeutics Presents Positive Full Data Set from LANTERN Phase 2 Study of LYR-210 at COSM 2021 Virtual
Mar 29, 2021 04:05PM Lyra Therapeutics to Present LANTERN Phase 2 Study Results for LYR‑210 in Oral Presentation at COSM 2021 Virtual
Mar 2, 2021 04:05PM Lyra Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
Feb 17, 2021 08:05AM Lyra Therapeutics (LYRA) Announces Appointment of Robert Kern, MD, as Chief Medical Officer
Feb 17, 2021 08:00AM Lyra Therapeutics Announces Appointment of Robert Kern, MD, as Chief Medical Officer
Jan 22, 2021 08:04AM Lyra Therapeutics (LYRA) Provides Corporate Update and Anticipated Milestones for 2021
Jan 22, 2021 08:00AM Lyra Therapeutics Provides Corporate Update and Anticipated Milestones for 2021
Dec 7, 2020 08:07AM Lyra Therapeutics (LYRA) Announces Positive Topline Results for LANTERN Phase 2 Randomized Controlled Study of LYR-210 for Treatment of Chronic Rhinosinusitis With and Without Nasal Polyps
Dec 7, 2020 08:00AM Lyra Therapeutics Announces Positive Topline Results for LANTERN Phase 2 Randomized Controlled Study of LYR-210 for the Treatment of Chronic Rhinosinusitis With and Without Nasal Polyps
Nov 12, 2020 04:05PM Lyra Therapeutics to Participate in Fireside Chat at the Jefferies Virtual London Healthcare Conference
Nov 10, 2020 04:05PM Lyra Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
View More Recent Stories